Stroke Recovery

Stroke happens when a clot blocks blood flow to part of the brain (ischemic stroke, about 80% of cases) or when a blood vessel breaks and bleeds into the brain (hemorrhagic stroke). Without oxygen and nutrients, brain cells begin to die within minutes, which is why stroke can cause lasting brain damage, long-term disability or death. Rehabilitation helps survivors relearn lost skills and regain independence. The AHA/ASA rehabilitation guideline describes it as a sustained, coordinated team effort involving physical and occupational therapists, speech-language pathologists, psychologists and others, with enough intensity and duration to matter.

Several peptides are promoted to support this process. Cerebrolysin is a peptide preparation made from pig brain. It is approved for stroke in more than 40 countries and widely used in Eastern Europe, Russia and China. Semax is a synthetic peptide based on a fragment of ACTH, developed in Russia, where it is an approved prescription drug for stroke and cognitive disorders. Cortexin, a brain-derived peptide preparation studied in Russian stroke trials, is the third answer to searches for a 'Russian stroke peptide.' BPC-157 is discussed in biohacking circles on the strength of rat studies. None of these is FDA-approved for stroke or for any other use in the United States.

If stroke symptoms are happening now, stop reading and call 911. Clot-dissolving drugs and clot removal work only within a limited time window, and no peptide is a substitute. This page covers what the evidence shows for peptides during recovery, including where independent reviews disagree with manufacturer-supported trials, and the drug-interaction issues that matter for stroke survivors. It is informational, not medical advice.

How peptides target stroke recovery

The peptides discussed for stroke aim at one of two goals. Some are meant to protect threatened brain cells in the first hours and days, an approach called neuroprotection. Others are meant to support recovery during rehabilitation, an approach called neurorestoration. Stroke research urges caution here. A 2006 review catalogued 1,026 experimental stroke treatments tested in animals, found that the 114 taken into human use had not been more effective in animal experiments than the rest, and linked this to the slow progress in developing stroke treatments. Every peptide claim deserves that skepticism.

Cerebrolysin is a mixture of low-molecular-weight peptides and free amino acids from purified pig brain proteins. It is described as having neurotrophic properties, meaning it is thought to act like the growth signals that support nerve-cell survival and repair. The rationale of the CARS trials was to give it during early rehabilitation, alongside a standardized therapy program, to enhance motor recovery. In trials it was given by daily intravenous infusion.

Semax is a synthetic analog of the ACTH(4–10) fragment, built from the ACTH(4–7) sequence plus a Pro-Gly-Pro tail (ACTH(4–7)PGP). It is given intranasally. In rodents it activates dopamine and serotonin systems in the brain. In rat models of cerebral ischemia, it changes the expression of immune, inflammatory and vascular genes. In a Russian clinical study it raised blood levels of brain-derived neurotrophic factor (BDNF). BPC-157's stroke rationale comes from rat studies in which the arteries supplying the brain were clamped and then released. Its developers attribute the observed protection to nitric-oxide-system and blood-vessel effects. None of these mechanisms has been confirmed as the cause of better human recovery.

What the evidence shows

Cerebrolysin has the most human trial data, and the findings depend on what you measure. The largest acute trial, CASTA (Heiss et al., Stroke 2012), randomized 1,070 patients in Asia within 12 hours of stroke onset to Cerebrolysin 30 mL daily or placebo for 10 days, on top of aspirin. Its primary endpoint was neutral. A post hoc analysis suggested benefit in more severe strokes, a signal that has not been confirmed in a dedicated trial. Trials during the rehabilitation window looked better. In CARS (Muresanu et al., Stroke 2016), patients started Cerebrolysin 30 mL daily or placebo 24–72 hours after stroke for 21 days, alongside standardized rehabilitation, and showed greater arm-function recovery at day 90. Its authors called the trial exploratory and asked for a larger confirmatory study. A pooled analysis of nine randomized trials (Bornstein et al., 2018; 1,879 patients) found earlier neurological improvement on the NIH Stroke Scale, with about 8 patients treated for one extra clinically relevant improvement. The manufacturer supported much of this literature.

Independent reviews are more cautious. The 2023 Cochrane review (Ziganshina et al.) pooled 7 randomized trials (1,773 participants) of Cerebrolysin or the similar preparation Cortexin, started within 48 hours of stroke. It found that they probably make little or no difference to all-cause death (RR 0.96, moderate certainty). None of the included trials reported the outcome that matters most to patients: death or dependence at the end of follow-up. Total serious adverse events did not differ (RR 1.16). However, non-fatal serious adverse events were more frequent with Cerebrolysin (RR 2.39, 95% CI 1.10–5.23, moderate certainty), especially at 30 mL daily for 10 days. Risk of bias was unclear across many trial domains. The review covered only treatment started within 48 hours, so rehabilitation-phase trials like CARS fall partly outside it.

Guidelines reflect this split. A 2021 guideline from the European Academy of Neurology and the European Federation of Neurorehabilitation Societies recommended Cerebrolysin (30 mL/day IV for at least 10 days) and citalopram (20 mg/day) for early motor rehabilitation after ischemic stroke. Cerebrolysin is not approved in the US and plays no part in standard US stroke care.

Semax's evidence is small, Russian-language and largely unreplicated. A 1997 study compared 30 acute-stroke patients given Semax with 80 conventionally treated controls and reported faster neurological recovery. A 2018 study of 110 patients in rehabilitation (Gusev et al.) compared those who did or did not receive Semax. Semax was linked to higher blood BDNF and faster gains on the Barthel daily-living index. Neither abstract describes a double-blind, placebo-controlled design, and no independent Western trial exists.

BPC-157 has no human stroke data. The main study (Vukojević et al., 2020) clamped both carotid arteries in rats for 20 minutes. BPC-157 was applied directly to the surgical site 30 seconds later, and the rats showed less hippocampal damage and full recovery on memory and coordination tests. That setup bears little resemblance to human stroke.

In short: Cerebrolysin has modest, mostly manufacturer-associated evidence for early recovery and a Cochrane safety signal. Semax has weak evidence. BPC-157 is preclinical.

What to expect

Where Cerebrolysin showed benefit, the effect was modest. It appeared as better scores on arm-function and stroke-severity scales over the first weeks to three months, in patients who were also getting intensive rehabilitation. The trial protocols used daily IV infusions of 30 mL for 10–21 days, started within days of the stroke, in hospital or rehabilitation settings. Those are supervised clinical regimens, not a home self-injection plan. Russian Semax protocols for stroke use short intranasal courses at milligram-level daily doses (12–18 mg/day for 5–10 days in the 1997 acute study, 6 mg/day courses in the 2018 rehabilitation study), far above nootropic doses, under physician care.

For chronic stroke, months or years later, there is essentially no trial evidence for any of these peptides; the trials started treatment within days of the stroke. Continued rehabilitation remains the evidence-based route at that stage. Do not expect any peptide to regrow dead brain tissue or reverse long-standing paralysis or aphasia.

Rehabilitation is the backbone of recovery. The AHA/ASA rehabilitation guideline calls comprehensive programs with adequate resources, dose and duration an essential part of stroke care. If a peptide is considered at all, it belongs as an adjunct discussed with the stroke team, never as a replacement for therapy hours.

Frequently asked questions

References

• Cerebrolysin for acute ischaemic strokeSystematic Review

  Ziganshina LE et al., Cochrane Database of Systematic Reviews 2023. 7 RCTs, 1,773 participants (Cerebrolysin or Cortexin, started within 48 hours). Little or no difference in all-cause death (RR 0.96). No trial reported death or dependence. More non-fatal serious adverse events with Cerebrolysin (RR 2.39, 95% CI 1.10–5.23), with moderate certainty of evidence.

• Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trialRandomized Controlled Trial
• Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter TrialRandomized Controlled Trial
• Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trialsMeta-Analysis
• European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic strokeReview

  Beghi E et al., European Journal of Neurology 2021. A GRADE-based guideline that recommends Cerebrolysin (30 mL/day IV, at least 10 days) and citalopram (20 mg/day) for early neurorehabilitation after acute ischemic stroke. It does not recommend amphetamines, fluoxetine, lithium or several other agents. This is the main guideline endorsement of Cerebrolysin, and it contrasts with the 2023 Cochrane findings.

• The efficacy of semax in the treatment of patients at different stages of ischemic strokeClinical Study
• The effect of pentadecapeptide BPC 157 on hippocampal ischemia/reperfusion injuries in ratsPreclinical
• Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke AssociationReview

Part of these goals

Related conditions

• Hypertension
• Brain Fog
• Depression
• Neuropathic Pain